Roche (RHHBY) signs an R&D collaboration agreement with immatics for cancer vaccines and immunotherapies "targeting primarily gastric, prostate, and non-small cell lung cancer."

immatics gets an upfront payment of $17M and is eligible for milestone payments up to and above $1B. immatics will also receive royalties on any marketed drugs.